Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
212M
-
Number of holders
-
205
-
Total 13F shares, excl. options
-
57.2M
-
Shares change
-
+1.63M
-
Total reported value, excl. options
-
$1.09B
-
Value change
-
+$32M
-
Put/Call ratio
-
1.25
-
Number of buys
-
105
-
Number of sells
-
-88
-
Price
-
$19.00
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q1 2018
241 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q1 2018.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 205 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 57.2M shares
of 212M outstanding shares and own 26.97% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (6.94M shares), BlackRock Inc. (6.69M shares), STATE STREET CORP (4.54M shares), FMR LLC (4.25M shares), WASATCH ADVISORS INC (3.69M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.3M shares), CREDIT SUISSE AG/ (1.93M shares), BAKER BROS. ADVISORS LP (1.61M shares), Casdin Capital, LLC (1.4M shares), and MORGAN STANLEY (1.24M shares).
This table shows the top 205 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.